MS Briefs

Fingolimod vs. natalizumab as second-line therapy for RRMS


Key clinical point : In patients with relapsing-remitting multiple sclerosis (RRMS), both fingolimod (FIN) and natalizumab (NTZ) reduce the annualized relapse rate (ARR), but ARR percent reduction is significantly higher with NTZ after 12 months of treatment.

Major finding : ARR reduction during the first year of treatment was statistically significant in both the groups, from 1.67±0.98 to 0.28±0.62 in the FIN group and from 1.71±1.37 to 0.12±0.33 in the NTZ group ( P less than .0001 for both). Nevertheless, the ARR percent reduction was significantly higher in the NTZ group vs. FIN group during the first year of treatment (92.3% vs. 81.8%; P = .0064).

Study details : Retrospective, observational study compared the ARR over the first year in 314 patients with RRMS after the treatment with FIN (n = 184) or NTZ (n = 130) as a second-line therapy in routine clinical practice in Spain.

Disclosures: This study was funding by Novartis Farmaceutica, S.A. The authors declared no conflicts of interest.

Citation: Meca-Lallana J et al. Eur Neurol. 2020 Mar 18. doi: 10.1159/000505778.

Next Article: